A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2018; you can also visit the original URL.
The file type is application/pdf
.
Archaebiotics: Archaea as Pharmabiotics for Treating Chronic Disease in Humans?
[chapter]
2017
Archaea - New Biocatalysts, Novel Pharmaceuticals and Various Biotechnological Applications
Recent indings highlight the role of the human gut microbiota in various disorders. For example, atherosclerosis frequently seems to be the consequence of gut microbiotaderived metabolism of some dietary components. Pharmabiotics (i.e., live/dead microbes and microbe-derived substances) and probiotics (live microorganisms with a health beneit when administered in adequate amounts) are a means to counteract these deleterious efects. Among the later, microbes now being used or, being currently
doi:10.5772/intechopen.69945
fatcat:kg333tlvxja45bkzwwyvw4cale